Tag results:
hepatic cells
Hepatic Cell News
Fibroblast-Derived Prolargin Is a Tumor Suppressor in Hepatocellular Carcinoma
[Oncogene] Investigators used proteomics and single cell RNA-sequencing analysis to examine the cancer-associated fibroblast landscape in hepatocellular carcinoma.
Hepatic Cell News
Sapidolide a Alleviates Acetaminophen-Induced Acute Liver Injury by Inhibiting NLRP3 Inflammasome Activation in Macrophages
[Acta Pharmacologica Sinica] Scientists investigated whether sapidolide A exerted protective effects on macrophages, thus alleviating the secondary hepatocyte damage in an acetaminophen-induced liver injury.
Hepatic Cell News
Tetramethylpyrazine Prevents Liver Fibrotic Injury in Mice by Targeting Hepatocyte-Derived and Mitochondrial DNA-Enriched Extracellular Vesicles
[Acta Pharmacologica Sinica] Researchers investigated whether tetramethylpyrazine exerted liver-protective action through regulating extracellular vesicle-dependent intercellular communication between hepatocytes and hepatic stellate cells.
Hepatic Cell News
MAPK p38/Ulk1 Pathway Inhibits Autophagy and Induces IL-1β Expression in Hepatic Stellate Cells
[American Journal of Physiology-Gastrointestinal and Liver Physiology] Investigators revealed a continuous signaling pathway, MAPK p38-Ulk1 phosphorylation-Ulk1/Atg13 disruption, which inhibited autophagy and induced IL-1β expression in hepatic stellate cells.
Hepatic Cell News
Traf3 Inactivation Promotes the Development of Intrahepatic Cholangiocarcinoma via NIK-Mediated Hepatocyte Transdifferentiation
[Hepatology] The authors performed a Sleeping Beauty transposon-based in vivo insertional mutagenesis screen in liver-specific Pten-deficient mice and identified tumor necrosis factor receptor-related factor 3 (Traf3) as the most significantly mutated gene in murine intrahepatic cholangiocarcinoma in a loss-of-function manner.
Hepatic Cell News
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis
[COUR Pharmaceuticals (PR Newswire, Inc.)] COUR Pharmaceuticals announced the US FDA granted Fast Track Designation to the company's investigational therapy CNP-104 for the treatment of primary biliary cholangitis.